Clinical trials: Urticaria Chronic
Chronic Spontaneous Urticaria
An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU
The main objective to assess the long-term safety and tolerability of LOU064 in patients with chronic spontaneous urticaria (CSU) who have participated in study CLOU064A2201 (NCT03926611)
- Trial name
- NCT04109313
- Testing
- LOU064
- Where
- 69 sites in United States, Argentina and 13 more
- Volunteers
- 229 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Adenoma, Colorectal Neoplasms
Adenoma Detection Rate in Colonoscopy Performed With EndoRings
The study is designed to examine whether colonoscopy using an EndoRings cap has a higher adenoma detection rate than conventional colonoscopy.
- Trial name
- NCT03219918
- Testing
- EndoRings II Distal Attachment
- Where
- Denmark
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Zealand University Hospital
Chronic Spontaneous Urticaria
Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)
Primary Objective: This study aimed to demonstrate the efficacy of dupilumab in study participants with CSU who remained symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naïve; Study B: omalizumab…
- Trial name
- NCT04180488
- Testing
- Dupilumab SAR231893, non sedating H1-antihistamine
- Where
- 98 sites in United States, Argentina and 9 more
- Volunteers
- 397 people
- Sponsor
- Sanofi
Chronic Spontaneous Urticaria
To Compare Efficacy and Safety of CT-P39 and EU-approved Xolair in Patients With Chronic Spontaneous Urticaria
A Double-blind, Randomized, Active-controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P39 and Xolair in Patients with Chronic Spontaneous Urticaria Who Remain Symptomatic despite H1 antihistamine…
- Trial name
- omalizumab (NCT04426890)
- Testing
- CT-P39, EU-approved Xolair
- Where
- Poland
- Volunteers
- 634 people
- Sponsor
- Celltrion
Chronic Urticaria
Real Life Use of Omalizumab in Chronic Urticaria
Chronic urticaria affects up to 1% of the population. Chronic urticaria refractory to updosing antihistamines can benefit from OMALIZUMAB, which is an anti-IgE IgG1 monoclonal antibody administrated every 4 weeks subcutaneously…
- Trial name
- XO-DS (NCT04584190)
- Where
- France
- Volunteers
- 700 people
- Sponsor
- University Hospital, Montpellier
Atopic Dermatitis, Alopecia Areata
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice.
- Conditions
- Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
- Trial name
- TARGET-DERM (NCT03661866)
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 15,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Chronic Urticaria
Chronic Urticaria - Long Term Assessment of Effects of Rupatadine
To compare CSU disease activity at the end of the follow up phase between patients that had been treated daily continuously vs. on-demand in the treatment phase
- Trial name
- NCT02358265
- Testing
- 10 mg Rupatadine on demand, 10 mg Rupatadine, 20 mg Rupatadine
- Where
- Germany
- Volunteers
- 192 people
- Sponsor
- Charite University, Berlin, Germany
Healthy Study Participants, Chronic Spontaneous Urticaria
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants
The purpose of the study is to assess safety, tolerability and pharmacokinetics (PK) of oral UCB8600.
- Trial name
- NCT04444466
- Testing
- UCB8600
- Where
- Bulgaria
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- UCB Biopharma SRL
Urticaria
High Dose Vitamin D Supplementation in Chronic Spontaneous Urticaria
Chronic spontaneous urticaria is an inflammatory disease which is characterized with intermittent or daily urticaria. This diseases lasts for more than 6 weeks.
- Trial name
- NCT02873364
- Testing
- Vitamin D3 (High dose), Vitamin D3 (Low dose)
- Where
- Iran
- Volunteers
- 80 people
- Sponsor
- Shiraz University of Medical Sciences
Urticaria
Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264
This First Time in Human (FTIH) study, which will be performed in three parts, is designed to investigate the safety, local tolerability, pharmacokinetics and pharmacodynamics after single and repeat topical applications of up to…
- Trial name
- NCT02424799
- Testing
- GSK2646264 0.5% topical cream, GSK2646264 1% topical cream
- Where
- 6 sites in Germany, United Kingdom
- Volunteers
- 34 people
- Sponsor
- GlaxoSmithKline
Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus
A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
Participants with diseases characterized by chronic pruritus experiencing moderate to severe pruritus will be enrolled in this pilot Phase 2 study.
- Conditions
- Chronic Idiopathic Urticaria, Chronic Idiopathic Pruritus, Lichen Planus, Lichen Simplex Chronicus
- Trial name
- NCT03858634
- Testing
- KPL-716
- Where
- 14 sites in United States
- Volunteers
- 58 people
- Sponsor
- Genentech, Inc.
Rhinitis, Urticaria
The Effect of Levocetirizine on Inflammatory Mediators in Dermatographism
Levocetirizine (Xyzal®), the active levorotatory enantiomer of cetirizine (Zyrtec®), is a FDA-approved drug used in the treatment of symptoms associated with seasonal and perennial allergic rhinitis and chronic idiopathic…
- Trial name
- NCT01008592
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University
Urticaria, Autoimmune Diseases
Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria
The aim of this study is to determine whether autologous adipose tissue derived Mesenchymal Stem Cells of treatment for chronic autoimmune urticaria is safe and effective.
- Conditions
- Urticaria, Autoimmune Diseases, Immune System Diseases, Skin Diseases
- Trial name
- NCT02824393
- Testing
- Autologous mesenchymal stem cell
- Where
- Turkey (Türkiye)
- Volunteers
- 10 people
- Sponsor
- Manisa Celal Bayar University
Chronic Spontaneous Urticaria
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines
The purpose of this study was to establish the efficacy, safety, and tolerability of Remibrutinib 25 mg b.i.d. in adult patients suffering from chronic spontaneous urticaria (CSU) inadequately controlled by second generation…
- Trial name
- REMIX-2 (NCT05032157)
- Testing
- LOU064 (blinded), LOU064 (open-label)
- Where
- 122 sites in United States, Austria and 16 more
- Volunteers
- 455 people
- Sponsor
- Novartis Pharmaceuticals
Urticaria Chronic
An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneous Urticaria
This is a Phase 2b, outpatient, single-dose, randomized, double blind, placebo-controlled, three period crossover study that will consist of a screening period and three blinded treatment periods.
- Trial name
- NCT06927999
- Testing
- 0.5 mg epinephrine, 1 mg epinephrine
- Where
- 3 sites in United States, Germany
- Volunteers
- 42 people
- Sponsor
- ARS Pharmaceuticals, Inc.
Chronic Spontaneous Urticaria
Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 36 subjects with moderate to severe Chronic Spontaneous Urticaria.
- Trial name
- NCT05373355
- Testing
- TLL018 tablets
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Chronic Spontaneous Urticaria
A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants
The purpose of this study is to evaluate safety, tolerability, immunogenicity, pharmacokinetics, pharmacodynamics, and efficacy of LP-003 in healthy volunteers.
- Trial name
- NCT06294288
- Testing
- LP-003 Dose 1 (Single), LP-003 Dose 2 (Single), LP-003 Dose 3 (Single)
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Longbio Pharma
Chronic Spontaneous Urticaria
Remibrutinib in Real-world Clinical Practice - a US Sub-study
Prospective, non-interventional study in patients with CSU where the treatment decision prior enrolment has been made to either escalate current sgH1-AHs treatment or escalate/switch current treatment to remibrutinib.
- Trial name
- REASSERT (NCT07358780)
- Where
- United States
- Volunteers
- 505 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Spontaneous Urticaria
A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria
This pilot and dose-ranging study will evaluate the efficacy, safety, and pharmacokinetics of MTPS9579A compared with placebo in participants with chronic spontaneous urticaria (CSU) refractory to antihistamines.
- Trial name
- NCT05129423
- Testing
- MTPS9579A
- Sponsor
- Genentech, Inc.
Asthma, Allergic Rhinitis
Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.
To investigate the Influence of Climatic and Environmental Factors on Respiratory or Allergic Diseases in Sanya.
- Conditions
- Asthma, Allergic Rhinitis, Chronic Obstructive Pulmonary Disease(COPD), Atopic Dermatitis
- Trial name
- NCT05330637
- Testing
- Climate and environment in Sanya
- Where
- China
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine